erk primary antibody Search Results


primary antibodies for total erk  (Merck KGaA)
90
Merck KGaA primary antibodies for total erk
Primary Antibodies For Total Erk, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/erk+primary+antibody/primary+antibodies+for+total+erk/pmc07429042-75-8-41
Average 90 stars, based on 1 article reviews
primary antibodies for total erk - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary antibodies specific to erk  (ETERLIFE LTD)
90
ETERLIFE LTD primary antibodies specific to erk
Melatonin, via the <t>ERK</t> pathway, regulates NPCs. (a–c) Melatonin significantly increased ERK1/2 activity above the concentration of 1 μ m. A slight inhibition of phosphorylated NF- κ B protein expression was detected at 1 μ M. A decrease in phosphorylation level of NF- κ B was also found at high concentrations of melatonin. No obvious change was observed in JNK activity after melatonin treatment. (d) Melatonin increased the proportion of cells in the S-phase and decreased that of cells in the G0/G1 phase. With U0126, the effects on cell cycle distribution were reduced. (e) Similarly, the expression of the cell cycle-related proteins was reduced in NPCs treated with melatonin and U0126. (f) Quantified analysis of cell cycle-related protein Western blot result. (g, h) The inhibition of apoptosis by melatonin was also reversed upon addition of U0126. (i) Quantified analysis of apoptosis-related protein Western blot result. (j) Western blot analysis also showed that, after addition of U0126, U0126 had a significant weakened role on melatonin in the downregulation <t>of</t> <t>collagen</t> X expression and there is no more positive effect from melatonin on aggrecan and collagen II expression in the NPCs. (k) Quantified analysis of cell matrix protein Western blot result ( ∗ p < 0.05).
Primary Antibodies Specific To Erk, supplied by ETERLIFE LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/erk+primary+antibody/primary+antibodies+specific+to+erk/pmc06914917-94-11-12
Average 90 stars, based on 1 article reviews
primary antibodies specific to erk - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary antibodies against jnk, p-jnk, erk, p-erk, p38, p-p38, gapdh  (Solarbio Inc)
90
Solarbio Inc primary antibodies against jnk, p-jnk, erk, p-erk, p38, p-p38, gapdh
Melatonin, via the <t>ERK</t> pathway, regulates NPCs. (a–c) Melatonin significantly increased ERK1/2 activity above the concentration of 1 μ m. A slight inhibition of phosphorylated NF- κ B protein expression was detected at 1 μ M. A decrease in phosphorylation level of NF- κ B was also found at high concentrations of melatonin. No obvious change was observed in JNK activity after melatonin treatment. (d) Melatonin increased the proportion of cells in the S-phase and decreased that of cells in the G0/G1 phase. With U0126, the effects on cell cycle distribution were reduced. (e) Similarly, the expression of the cell cycle-related proteins was reduced in NPCs treated with melatonin and U0126. (f) Quantified analysis of cell cycle-related protein Western blot result. (g, h) The inhibition of apoptosis by melatonin was also reversed upon addition of U0126. (i) Quantified analysis of apoptosis-related protein Western blot result. (j) Western blot analysis also showed that, after addition of U0126, U0126 had a significant weakened role on melatonin in the downregulation <t>of</t> <t>collagen</t> X expression and there is no more positive effect from melatonin on aggrecan and collagen II expression in the NPCs. (k) Quantified analysis of cell matrix protein Western blot result ( ∗ p < 0.05).
Primary Antibodies Against Jnk, P Jnk, Erk, P Erk, P38, P P38, Gapdh, supplied by Solarbio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/erk+primary+antibody/primary+antibodies+against+jnk++p+jnk++erk++p+erk++p38++p+p38++gapdh/pmc08751615-75-21-24
Average 90 stars, based on 1 article reviews
primary antibodies against jnk, p-jnk, erk, p-erk, p38, p-p38, gapdh - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary antibodies against erk  (iReal Biotechnology Inc)
90
iReal Biotechnology Inc primary antibodies against erk
Melatonin, via the <t>ERK</t> pathway, regulates NPCs. (a–c) Melatonin significantly increased ERK1/2 activity above the concentration of 1 μ m. A slight inhibition of phosphorylated NF- κ B protein expression was detected at 1 μ M. A decrease in phosphorylation level of NF- κ B was also found at high concentrations of melatonin. No obvious change was observed in JNK activity after melatonin treatment. (d) Melatonin increased the proportion of cells in the S-phase and decreased that of cells in the G0/G1 phase. With U0126, the effects on cell cycle distribution were reduced. (e) Similarly, the expression of the cell cycle-related proteins was reduced in NPCs treated with melatonin and U0126. (f) Quantified analysis of cell cycle-related protein Western blot result. (g, h) The inhibition of apoptosis by melatonin was also reversed upon addition of U0126. (i) Quantified analysis of apoptosis-related protein Western blot result. (j) Western blot analysis also showed that, after addition of U0126, U0126 had a significant weakened role on melatonin in the downregulation <t>of</t> <t>collagen</t> X expression and there is no more positive effect from melatonin on aggrecan and collagen II expression in the NPCs. (k) Quantified analysis of cell matrix protein Western blot result ( ∗ p < 0.05).
Primary Antibodies Against Erk, supplied by iReal Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/erk+primary+antibody/primary+antibodies+against+erk/pmc07738970-101-2-16
Average 90 stars, based on 1 article reviews
primary antibodies against erk - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary antibodies against erk  (Abfrontier ltd)
90
Abfrontier ltd primary antibodies against erk
Melatonin, via the <t>ERK</t> pathway, regulates NPCs. (a–c) Melatonin significantly increased ERK1/2 activity above the concentration of 1 μ m. A slight inhibition of phosphorylated NF- κ B protein expression was detected at 1 μ M. A decrease in phosphorylation level of NF- κ B was also found at high concentrations of melatonin. No obvious change was observed in JNK activity after melatonin treatment. (d) Melatonin increased the proportion of cells in the S-phase and decreased that of cells in the G0/G1 phase. With U0126, the effects on cell cycle distribution were reduced. (e) Similarly, the expression of the cell cycle-related proteins was reduced in NPCs treated with melatonin and U0126. (f) Quantified analysis of cell cycle-related protein Western blot result. (g, h) The inhibition of apoptosis by melatonin was also reversed upon addition of U0126. (i) Quantified analysis of apoptosis-related protein Western blot result. (j) Western blot analysis also showed that, after addition of U0126, U0126 had a significant weakened role on melatonin in the downregulation <t>of</t> <t>collagen</t> X expression and there is no more positive effect from melatonin on aggrecan and collagen II expression in the NPCs. (k) Quantified analysis of cell matrix protein Western blot result ( ∗ p < 0.05).
Primary Antibodies Against Erk, supplied by Abfrontier ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/erk+primary+antibody/primary+antibodies+against+erk/pm23454146-91-29-32
Average 90 stars, based on 1 article reviews
primary antibodies against erk - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Melatonin, via the ERK pathway, regulates NPCs. (a–c) Melatonin significantly increased ERK1/2 activity above the concentration of 1 μ m. A slight inhibition of phosphorylated NF- κ B protein expression was detected at 1 μ M. A decrease in phosphorylation level of NF- κ B was also found at high concentrations of melatonin. No obvious change was observed in JNK activity after melatonin treatment. (d) Melatonin increased the proportion of cells in the S-phase and decreased that of cells in the G0/G1 phase. With U0126, the effects on cell cycle distribution were reduced. (e) Similarly, the expression of the cell cycle-related proteins was reduced in NPCs treated with melatonin and U0126. (f) Quantified analysis of cell cycle-related protein Western blot result. (g, h) The inhibition of apoptosis by melatonin was also reversed upon addition of U0126. (i) Quantified analysis of apoptosis-related protein Western blot result. (j) Western blot analysis also showed that, after addition of U0126, U0126 had a significant weakened role on melatonin in the downregulation of collagen X expression and there is no more positive effect from melatonin on aggrecan and collagen II expression in the NPCs. (k) Quantified analysis of cell matrix protein Western blot result ( ∗ p < 0.05).

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Melatonin Protects Intervertebral Disc from Degeneration by Improving Cell Survival and Function via Activation of the ERK1/2 Signaling Pathway

doi: 10.1155/2019/5120275

Figure Lengend Snippet: Melatonin, via the ERK pathway, regulates NPCs. (a–c) Melatonin significantly increased ERK1/2 activity above the concentration of 1 μ m. A slight inhibition of phosphorylated NF- κ B protein expression was detected at 1 μ M. A decrease in phosphorylation level of NF- κ B was also found at high concentrations of melatonin. No obvious change was observed in JNK activity after melatonin treatment. (d) Melatonin increased the proportion of cells in the S-phase and decreased that of cells in the G0/G1 phase. With U0126, the effects on cell cycle distribution were reduced. (e) Similarly, the expression of the cell cycle-related proteins was reduced in NPCs treated with melatonin and U0126. (f) Quantified analysis of cell cycle-related protein Western blot result. (g, h) The inhibition of apoptosis by melatonin was also reversed upon addition of U0126. (i) Quantified analysis of apoptosis-related protein Western blot result. (j) Western blot analysis also showed that, after addition of U0126, U0126 had a significant weakened role on melatonin in the downregulation of collagen X expression and there is no more positive effect from melatonin on aggrecan and collagen II expression in the NPCs. (k) Quantified analysis of cell matrix protein Western blot result ( ∗ p < 0.05).

Article Snippet: For immunohistochemistry detection, sections were incubated with primary antibodies specific to ERK (EterLife, UK), collagen II (Novus Biologicals, CO, USA), and collagen X (Biosynthesis Biotech, China).

Techniques: Activity Assay, Concentration Assay, Inhibition, Expressing, Phospho-proteomics, Western Blot

(a) Magnetic resonance imaging findings after melatonin injection on rabbit intervertebral discs. T2 signal intensity was stronger for the melatonin-injected discs than for the saline discs, including the melatonin plus U01256 group. (b) Thompson score showed the significant radiological improvement on the 8th week brought by melatonin ( ∗ p < 0.05). (c) Histological analysis on intervertebral discs by HE staining. More chondrocytes with intact annulus fibrosus were observed in the melatonin-treated rats. However, reduced number of chondrocytes and twisted or damaged annulus fibrosus presented in the two control groups. ERK 1/2 immunohistochemical staining indicates that ERK 1/2 expression was more apparent in the melatonin group. Quantification of immunohistochemical staining showed that the melatonin group had significantly higher mean optical density than the inhibitor-treated and control groups. Collagen II and X immunohistochemical staining indicates that collagen II was detected in the melatonin-treated group, but little in the two control groups. By contrast, the staining for collagen X was weaker in the melatonin-treated group. Quantification of collagen II immunohistochemical staining showed that the melatonin-treated discs had significantly higher mean optical density than the control groups and the expression of collagen X was significantly lower. (d) Quantified analysis of immunohistochemical staining showed the significant histological improvement brought by melatonin via the ERK pathway ( ∗ p < 0.05).

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Melatonin Protects Intervertebral Disc from Degeneration by Improving Cell Survival and Function via Activation of the ERK1/2 Signaling Pathway

doi: 10.1155/2019/5120275

Figure Lengend Snippet: (a) Magnetic resonance imaging findings after melatonin injection on rabbit intervertebral discs. T2 signal intensity was stronger for the melatonin-injected discs than for the saline discs, including the melatonin plus U01256 group. (b) Thompson score showed the significant radiological improvement on the 8th week brought by melatonin ( ∗ p < 0.05). (c) Histological analysis on intervertebral discs by HE staining. More chondrocytes with intact annulus fibrosus were observed in the melatonin-treated rats. However, reduced number of chondrocytes and twisted or damaged annulus fibrosus presented in the two control groups. ERK 1/2 immunohistochemical staining indicates that ERK 1/2 expression was more apparent in the melatonin group. Quantification of immunohistochemical staining showed that the melatonin group had significantly higher mean optical density than the inhibitor-treated and control groups. Collagen II and X immunohistochemical staining indicates that collagen II was detected in the melatonin-treated group, but little in the two control groups. By contrast, the staining for collagen X was weaker in the melatonin-treated group. Quantification of collagen II immunohistochemical staining showed that the melatonin-treated discs had significantly higher mean optical density than the control groups and the expression of collagen X was significantly lower. (d) Quantified analysis of immunohistochemical staining showed the significant histological improvement brought by melatonin via the ERK pathway ( ∗ p < 0.05).

Article Snippet: For immunohistochemistry detection, sections were incubated with primary antibodies specific to ERK (EterLife, UK), collagen II (Novus Biologicals, CO, USA), and collagen X (Biosynthesis Biotech, China).

Techniques: Magnetic Resonance Imaging, Injection, Saline, Staining, Control, Immunohistochemical staining, Expressing